Edwards Lifesciences Critical Care
2024
$4.2B
Outcome
Integrated into BD Interventional / Advanced Monitoring.
Becton Dickinson
Medical TechnologyFounded 1897- HQ today: Franklin Lakes, New Jersey, United States
Reviewed by Swet Parvadiya
Company data updated: October 2026
Acquisitions
Becton Dickinson Acquisitions
4
Major Deals Covered
$40.4B
Disclosed Deal Value
What are Becton Dickinson's biggest acquisitions?
Becton Dickinson's largest disclosed acquisition here is C.R. Bard for $24 in 2017. This page covers 4 major deals from 2015 to 2024, each with its price where disclosed and the reason behind it.
- Major deals covered
- 4
- Largest deal
- C.R. Bard ($24)
- First deal
- 2015
- Most recent
- 2024
| Company | Year | Price | Purpose |
|---|---|---|---|
| CareFusion | 2015 | Undisclosed | — |
| C.R. Bard | 2017 | Undisclosed | — |
| Edwards Lifesciences Critical Care | 2024 | Undisclosed | — |
| Vyaire Medical (Respiratory assets) | 2021 | Undisclosed | — |
- What companies has Becton Dickinson bought?
- Major acquisitions by Becton Dickinson documented here include C.R. Bard (2017), CareFusion (2015), Edwards Lifesciences Critical Care (2024) and Vyaire Medical (Respiratory assets) (2021).
- What is Becton Dickinson's most recent acquisition?
- The most recent Becton Dickinson acquisition documented here is Edwards Lifesciences Critical Care, in 2024, for $4.2.
Vyaire Medical (Respiratory assets)
2021
Outcome
Successfully integrated.
C.R. Bard
2017
$24.0B
Outcome
Highly accretive segment driving advanced interventional growth.
CareFusion
2015
$12.2B
Outcome
Fully integrated into BD Medication Management Solutions.
Becton Dickinson's Growth & Acquisition Strategy
Scaling smart connected medication management, expanding interventional and critical care monitoring portfolios, growing home healthcare devices, and driving operational efficiencies.
How Becton Dickinson Makes Money
BD operates a high-leverage commercial model anchored by consumable hospital supplies and recurring razor-and-blade device ecosystems. It generates revenue through three core segments: Medical (consumables, syringes, infusion systems), Interventional (surgical, vascular, critical care), and Life Sciences (Vacutainer blood collection tubes and diagnostic instruments).
Becton Dickinson Acquisitions FAQ
What is Becton, Dickinson and Company's general approach to M&A and acquisitions?
Becton, Dickinson and Company pursues a disciplined, strategic M&A approach focused on acquiring proprietary technologies, expanding customer distribution reach, and unlocking operational cost synergies rather than pursuing unselective scale.
What were some of the most transformative acquisitions completed by Becton, Dickinson and Company?
Transformative transactions in Becton, Dickinson and Company's history include pivotal mergers and acquisitions that secured key regional footprints, consolidated core market share, and brought proprietary software intellectual property in-house.
How does Becton, Dickinson and Company successfully integrate acquired companies?
Becton, Dickinson and Company deploys dedicated integration teams to harmonize core software stacks, align regulatory compliance systems, and unite company cultures while preserving entrepreneurial agility.
Does Becton, Dickinson and Company divest non-core corporate assets?
Yes, Becton, Dickinson and Company periodically evaluates its corporate portfolio, strategically divesting non-core or non-strategic assets to redeploy capital into high-margin core operational divisions.
Related M&A Histories
Compare corporate acquisition records, deal values, and strategic targets
Explore Becton Dickinson
Core profile pages, founders and related research hubs for this company.